Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes. Researchers at Weill Cornell Medicine, New York-Presbyterian and Memorial Sloan ...

The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the ...

Researchers at the University of California San Diego have discovered two distinct molecular subtypes of Crohn’s disease by studying organoids derived from adult stem cells in the intestine tissue ...

Results from Pistoia Alliance’s Lab of the Future survey has shared important findings about the challenges life science companies face. The results from The Pistoia Alliance’s Lab of the Future ...

Proscia has launched two new products which will help to accelerate discovery and development of new therapies and diagnostics.

Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.

Sphere Fluidics have developed the Cyto-Mine® Chroma platform, which provides multiplexing and greater assay flexibility, reducing timelines and cost.

Results from Pistoia Alliance’s Lab of the Future survey has shared important findings about the challenges life science companies face.

Curiosity about the functioning of the human body and a genuine desire to benefit others drew Gilda Ascione into the world of medicine. Here, Dr Ascione, Medical Director Oncology at Daiichi Sankyo ...

Eurofins Discovery’s Luke Oostdyk, PhD, will highlight anti-obesity target combination therapies and cell-based assays ideal for testing functional activity, specificity, potency and signalling ...

With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies ...